SELLAS Life Sciences Group, Inc. (SLS) is a Biotechnology company in the Healthcare sector, currently trading at $4.86. It has a SharesGrow Score of 53/100, indicating a mixed investment profile with 3 out of 7 criteria passed.
Analyst consensus target is SLS = $3 (-42.4% upside).
Valuation: SLS trades at a trailing Price-to-Earnings (P/E) of -27.4 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.75.
Net income is $27M (loss), growing at +13.3%/yr. Net profit margin is 0% (thin). Gross margin is 90% (+0 pp trend).
Balance sheet: total debt is $1M against $71M equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 10.72 (strong liquidity). Debt-to-assets is 1.3%. Total assets: $78M.
Analyst outlook: 5 / 5 analysts rate SLS as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 63/100 (Pass), Growth 48/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 52/100 (Partial), Future 64/100 (Pass), Income ?/100 (Fail).
